Genetic loci on chromosome 5 are associated with circulating levels of interleukin-5 and eosinophil count in a European population with high risk for cardiovascular disease by O. Mcleod et al.
1 
 
 
Genetic loci on chromosome 5 are associated with circulating levels of interleukin-5 and 
eosinophil count in a European population with high risk for cardiovascular disease  
 
Olga McLeoda, Angela Silveiraa, Elsa Valdes-Marquezb, Harry Björkbackac, Peter Almgrend 
Karl Gertowa, Jesper R. Gådina, Alexandra Bäcklunda, Bengt Sennblada,e, Damiano 
Baldassarref,g, Fabrizio Vegliag, Steve E. Humphriesh, Elena Tremolif,g, Ulf de Fairei, Jan 
Nilssonc, Olle Melanderd, Jemma C Hopewellb, Robert Clarkeb, Hanna M. Björcka, Anders 
Hamstena, John Öhrvika and Rona J. Strawbridgea on behalf of the IMPROVE study group 
 
aCardiovascular Medicine Unit, Department of Medicine Solna, Karolinska Institutet, 
Stockholm, Sweden. 
bCTSU – Nuffield Department of Population Health, University of Oxford, Oxford, UK 
cExperimental Cardiovascular Research Unit, Dept. of Clincal Sciences Malmö, Lund 
Univeristy, Malmö, Sweden. 
dDepartment of Clinical Sciences, Malmö, Lund University, Malmö, Sweden 
eCardiovascular Medicine Unit, Department of Medicine, Science for Life 
Laboratory, Karolinska Institutet, Stockholm, Sweden. 
fDipartimento di Scienze Farmacologiche e Biomolecolari, Università di Milano  
gCentro Cardiologico Monzino, IRCCS, Milan, Italy. 
hCentre for Cardiovascular Genetics, University College London, United Kingdom. 
iDivision of Cardiovascular Epidemiology, Institute of Environmental Medicine, Karolinska 
Institutet, Stockholm, Sweden. 
 
Correspondence to: 
Rona J Strawbridge 
L8:03, Centre for Molecular Medicine,  
Karolinska Universitetsjukhuset 
Solna, 171 76 
Stockholm 
 
 
 
 
2 
 
Abstract 
IL-5 is a Th2 cytokine which activates eosinophils and is suggested to have an 
atheroprotective role. Genetic variants in the IL5 locus have been associated with increased 
risk of CAD and ischemic stroke. In this study we aimed to identify genetic variants 
associated with IL-5 concentrations and apply a Mendelian randomisation approach to assess 
IL-5 levels for causal effect on intima-media thickness in a European population at high risk 
of coronary artery disease.  We analysed SNPs within robustly associated candidate loci for 
immune, inflammatory, metabolic and cardiovascular traits. We identified 2 genetic loci for 
IL-5 levels (chromosome 5, rs56183820, BETA= 0.11, P= 6.73E-5 and chromosome 14, 
rs4902762, BETA= 0.12 , P= 5.76E-6) and one for eosinophil count (rs72797327, BETA= -
0.10, P= 1.41E-6). Both chromosome 5 loci were in the vicinity of the IL5 gene, however the 
association with IL-5 levels failed to replicate in a meta-analysis of 2 independent cohorts 
(rs56183820, BETA= 0.04, P= 0.2763, I2 =24, I2-P = 0.2516). No significant associations 
were observed between SNPs associated with IL-5 levels or eosinophil count and IMT 
measures. Expression quantitative trait analyses indicate effects of the IL-5 and eosinophil-
associated SNPs on RAD50 mRNA expression levels (rs12652920 (r2=0.93 with rs56183820) 
BETA= -0.10, P=8.64E-6 and rs11739623 (r2= 0.96 with rs72797327) BETA= -0.23, 
P=1.74E-29, repsectively). Our data do not support a role for IL-5 levels and eosinophil count 
in intima-media thickness, however SNPs associated with IL-5 and eosinophils might 
influence stability of the atherosclerotic plaque via modulation of RAD50 levels.  
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IMTmean-max  Mean of the maximum IMT measures along the entire carotid tree 
IMT-CCmean Mean of IMT measures in the common carotid 
IMT-CCmax  Max of IMT measures in the common carotid  
IMT-Bifmean  Mean of IMT measures in the carotid bifurcation  
IMT-Bifmax  Max of IMT measures in the carotid bifurcation 
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1. Introduction 
Atherosclerosis is a process leading to coronary artery disease (CAD) and ischemic stroke, 
and is among the leading causes of mortality and morbidity throughout the world [1]. It is 
thought that a key component of atherosclerosis is lipid accumulation in the arterial wall, 
leading to leukocyte recruitment, inflammation and participation of both innate and adaptive 
immune responses. To support the immune responses hypothesis, a number of immune or 
inflammatory biomarkers for cardiovascular disease (CVD) have been investigated. Some, 
such as C-reactive protein (CRP), appear to reflect general disease processes [2, 3],whereas a 
number of cytokines (such as IL-1, IL-2, IL-6, IL-8, IL-10, IL-12, IL-17 and TNFα) are 
robustly associated with CVD and are thought to be actively involved in the inflammatory 
processes leading to atherosclerosis [4, 5]. 
Genetic studies have identified single nucleotide polymorphisms (SNPs) that are associated 
with increased risk of CAD in the interleukin-5 gene (IL5) [6] and increased risk of ischemic 
stroke in the interleukin-5 receptor alpha subunit gene (IL5RA) [7]. As with most genetic 
variants associated with CVD, the mechanism by which the IL5 SNP influences disease is 
unclear. A number of studies (including one from our group) have also proposed an athero-
protective role for IL-5 [8-11], which is supported by the fact that it is produced mainly by 
anti-inflammatory T helper 2 (Th2) cells. In addition to activated Th2 cells, IL-5 can be 
produced by mast cells and to a lesser extent by eosinophils. IL-5 is a growth and 
differentiation factor for B-cells, an immunoglobulin-A (IgA)-enhancing factor and a key 
cytokine in eosinophil maturation, differentiation, activation and survival [12, 13]; thus, it is 
interesting that the IL5 locus has also been associated with eosinophil count [14]. Cellular 
responses are dependent upon IL-5 activating a dimeric receptor consisting of an α and a β-
subunit. The β-subunit is shared with IL-3 and granulocyte-macrophage colony-stimulating 
factor (GM-CSF) [15], however the α-subunit is specific to IL-5. Thus, availability of the α-
chain on the cell surface controls responsiveness of the cell to IL-5 [16, 17].  
Thickness of the intima-media layer of the carotid artery can be considered a marker of 
cardiovascular risk. Differences in carotid intima-media thickness (IMT) over time can be 
indicative of changes in the structure, and possibly functions, of the vessel wall. The aims of 
this study were to identify genetic variants associated with IL-5 levels and to use these in a 
Mendelian randomisation approach to assess IL-5 levels for causal effects on carotid IMT. As 
eosinophil count and IL-5 levels are inter-related, we also investigated the genetic regulation 
of eosinophil count. We used the prospective IMPROVE study (the Carotid Intima Media 
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Thickness [IMT] and IMT-Progression as Predictors of Vascular Events in a High Risk 
European Population study), which is based on 3,703 subjects at high risk of CVD with 
extensive genetic data, biochemical phenotyping and repeat detailed ultra-sound 
measurements of the carotid artery IMT [18, 19]. Genetic markers robustly associated with 
increased levels of a biomarker or constituting a causal component of increased IMT should 
be useful for risk stratification and early prevention of CVD. 
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2. Materials and Methods 
 
2.1 Discovery cohort: the IMPROVE cohort 
The design features, biobank and dataset of the IMPROVE study have been reported [18, 19]. 
Of 3,703 participants with at least three cardiovascular risk factors but without symptoms or 
diagnosed prevalent disease, 3,435 passed phenotypic quality control and were considered for 
the current study. Ethics committee approval for the study was obtained from each centre and 
written informed consent was obtained from all participants. 
 
2.2  Phenotypes 
A wide range of anthropometric and biochemical measurements were acquired, including 
fasting concentrations of HDL and LDL cholesterol (by Friedewald's formula), triacylglycerol 
(TG), high sensitivity CRP (hs-CRP), creatinine and plasma glucose as described [19]. 
Diabetes was defined as diagnosis of diabetes and/or fasting blood glucose ≥7 mmol/L and/or 
glucose lowering treatment. Levels of IL-5 were measured in EDTA-plasma samples using 
the ultra-sensitive kit for human IL-5 (MesoScale Discovery, Gaithersburg, MD, USA) 
following instructions provided by the manufacturer. Details of the high-resolution ultrasound 
measurements of carotid IMT at baseline and follow-up have been reported [18, 19]. A 
number of studies suggested that atherosclerotic changes can be site-specific and have distinct 
clinical implications [20-22]. Thus one composite and four segment-specific measurements of 
carotid IMT by were included in the study: IMTmean-max (mean of the maximum IMT measures 
along the entire carotid tree), IMT-CCmean and IMT-CCmax (mean and maximum of common 
carotid segment), IMT-Bifmean and IMT-Bifmax (mean and maximum of the bifurcation). The 
ultrasonographic measurements were obtained at baseline and after 15 and 30 months. These 
three time points were used in linear regression to assess change over time in IMT [18], 
referred to here as progression of IMT. Characteristics of the IMPROVE cohort with available 
genetic and phenotypic data (n=3,435) are presented in Table 1. 
  
2.3 Genetic analysis 
Genotyping was performed using Illumina 200K Cardio-Metabochip [23]and Immunochip 
[24] genotyping arrays (hence referred to as the combined chip). Whilst the combined chips 
do not have genome-wide coverage, they do have good coverage of candidate or robustly 
associated loci for immune, inflammatory, metabolic and cardiovascular traits, which allows 
for a less conservative threshold for significance compared to genome-wide platforms. 
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Genotyping and calling were performed at the SNP Technology Platform (Uppsala 
University, Sweden Uppsala). Standard genetic quality control procedures were followed with 
exclusions for SNPs failing call rate (<95%) and Hardy-Weinberg (p<5E-7) checks or with 
minor allele frequency (MAF) <1% and for subjects with cryptic relatedness or sex check 
failures. After quality control, 3,433 individuals with genetic and phenotypic data were 
included in the analysis. 
 
2.4 Replication cohorts: the PROCARDIS and MDC cohorts 
Replication was sought in the PROCARDIS [25] and MDC cohorts [26, 27].  
The PROCARDIS cohort consists of cases and controls from the UK, Sweden, Italy and 
Germany. All cases were diagnosed with CAD before the age of 66 years and most (80%) had 
a sibling with CAD before 66 years. Controls were recruited from the same populations and 
did not have a diagnosis of CAD, or a sibling with diagnosis of CAD, before 66 years of age. 
Plasma levels of IL-5 were measured in duplicate on the same plate by a sandwich 
immunoassay with electrochemiluminescence detection using a MesoScale Diagnostics 
platform (Gaithersburg, Maryland, USA). Genomewide genotyping of PROCARDIS was 
conducting using the Illumina 1M or 610K platforms. Genotype calling was performed at the 
Centre National du Genotypage, Paris or the Uppsala SNP Genotyping platform, Sweden. 
Standard quality control was conducted as detailed above. 
The Malmö Diet and Cancer (MDC) study is a prospective population-based cohort study 
including 28,449 subjects recruited during 1991–1996. Subjects aged 45–69 years, living in 
Malmö, Sweden were eligible for participation. Between November 1991 and February 1994, 
every second enrolled subject was also invited to take part in a substudy of the epidemiology 
of carotid artery disease. This MDC-CardioVascular cohort consists of 6103 subjects (60% 
women), 5540 of whom also agreed to have blood collected under standardized fasting 
conditions. MDC was genotyped using the Illumina OmniExpressExome chip and standard 
quality control was conducted as detailed above. The methodology used for measuring IL-5 
levels has previously been described [28]. Briefly, levels of cytokines released by 
mononuclear cells after stimulation (with CD3/CD28 beads) were analysed using a multiplex 
cytokine immunoassay (MesoScale Discovery, Gaithersburg, MD, USA).  
Whilst the genotyping platforms utilised by the discovery and replication cohorts are not the 
same, all 3 platforms are produced by the same company and based upon the same bead chip 
technology. In addition, the same quality control parameters are used for the genotype calling, 
as well as for the downstream analyses (as detailed above). 
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2.5 Statistical methods 
Differences between two groups according to sex were assessed by Wilcoxon Mann-Whitney 
ranksum test for continuous variables and Fisher's exact test for binary variables (Table 1). 
Since a sex difference in IL-5 levels has been observed [11], we adjusted for sex. Risk factors 
and biomarkers significantly associated with plasma levels of IL-5 (by Spearman rank 
correlation) were considered for inclusion in regression models. Variables with skewed 
distributions were log-transformed prior to regression analysis. In both the analyses of IL-5 
and of eosinophil count, the basic model was adjusted for population structure (as assessed by 
the first 3 multi-dimensional scaling components), age and sex. For IL-5 analyses, the 
extended model also included LDL and hsCRP. For eosinophil count, the extended model 
included BMI, fasting proinsulin concentration and white blood count. Variables for inclusion 
in the extended model were determined by backward stepwise selection in a multiple 
regression model. Linear regression analysis was used to assess associations between SNP 
genotypes and plasma IL-5 concentrations or eosinophil count, assuming an additive genetic 
model. The threshold for replication was set at p <1.00E-5, whereas array-wide significance 
was set at p <1.92E-7 (based on the calculation of the number of uncorrelated SNPs on the 
combined Metabo-Immuno chips as previously described [29]). Linear regression assuming 
an additive genetic model was also used for analysis of IMT measures, with adjustment for 
age, sex and population structure. Further adjustment for established CVD risk markers 
included age, sex, population structure, BMI, SBP, HDL, TG, hsCRP, current smoking and 
type 2 diabetes. 
Replication analyses were conducted in the same manner as the discovery analyses, but the 
models were amended for PROCARDIS, where country was used instead of MDS 
components and case-control status was included as a covariate. Statistical analyses were 
performed in STATA (Statacorp, Houston, TX, USA) except chip-wide genetic analyses 
which were conducted using PLINK [30]. Because of high correlation between IMT 
measurements of carotid segments [19], correction for testing multiple phenotypes was not 
applied.  
 
2.6 Gene expression analysis  
Differential gene expression analysis for SNPs robustly associated with plasma IL-5 
concentrations was performed. Firstly, in the Advanced Study of Aortic Pathology (ASAP) 
[31], where aortic adventitia (n=132), aortic media (n=137) and heart (n=127) tissue samples 
8 
 
were analysed. In brief, tissue samples were collected from patients undergoing elective 
surgery for aortic aneurysm and/or aortic valve repair. RNA was extracted from biopsy 
material and hybridised to Affymetrix ST 1.0 exon arrays (Santa Clara, CA, USA). DNA was 
extracted from whole blood and genotyped on the Illumina 610w-Quad Bead Array (San 
Diego, CA, USA). SNPs with call rate >95% were used for imputation, and imputed SNPs 
with quality scores of MACH <0.3 were excluded. The ASAP study was approved by the 
ethics committee at Karolinska Institutet. Associations between SNP genotypes and gene 
expression were assessed assuming an additive genetic model. Significance was set at 
p<0.0056 (Bonferroni-correction for 3 SNPs in 3 tissues). Secondly the publicly available 
MuTHER gene expression data was also interrogated [32]. Of the IL-5 or eosinophil-
associated SNPs identified in IMPROVE, 5 were available in the MuTHER dataset, thus 
p<0.01 (Bonferroni-correction for 5 SNPs in one tissue) was set for the level of significance. 
Finally, the publically available rSNPBase [33] was searched effects of SNPs on gene 
expression. As the data in this resource is qualitative, no threshold for significance was 
employed.  
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3. Results 
 
3.1 Cardiovascular, metabolic, inflammatory or immune-associated SNPs vs IL-5 levels or 
eosinophil count 
In order to assess whether there are SNPs in loci previously associated with immune, 
inflammatory, metabolic or CVD traits which influence plasma levels of IL-5 or eosinophil 
count, the combined chip was analysed. When considering IL-5 levels, there were no genetic 
variants that demonstrated array-wide significant associations (i.e. p <1.92E-7), however 2 loci 
reached the threshold set for replication (p<1.00E-5, Figure 1, Upper panel and Table 2). 
Further adjustment using the extended model had a negligible effect on the results (Table 2). 
The chromosome 14 locus consists of a single SNP (Supplementary Figure 1), whilst the 
chromosome 5 locus (defined by the positions of the first and last SNPs reaching p<1.00E-5 in 
the region) encompasses 79 SNPs extending across and upstream of the IL5 gene.  When 
considering associations with eosinophil count, one locus, including 14 SNPs, reached the 
threshold for replication but not array-wide significance (Figure 1, Lower panel and Table 2) 
in both the basic and extended models (Table 2). This locus is also on chromosome 5 and 
extends across the IL5 gene. 
 
3.2 Genetic architecture of IL5 and eosinophil-associated loci 
Given that only a single SNP was genotyped in the chromosome 14 locus, it is hard to say 
anything about the genetic architecture of this locus. More genotyping in this region would be 
needed to further explore this locus.  
The 2 loci on chromosome 5 discovered here are located in physical proximity to each other, 
however the SNPs in the 2 loci are distinct and appear to be independent from each other by 
linkage disequilibrium (LD, Figure 2, Upper and Lower panels, Supplementary Figure 2). The 
3 genetic markers in the vicinity of the IL5 gene reported in earlier studies were independent 
from each other and the loci identified in the current study as assessed by LD (Supplementary 
Figure 2), however the eosinophil-associated SNP (rs4143832) and the CVD-associated SNP 
(rs2706399) fell within our eosinophil-associated locus. To further test the independence of 
the 2 loci, conditional analysis was conducted, whereby the IL-5 analysis was adjusted for the 
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lead eosinophil-associated SNP and vice versa. As demonstrated in Table 3, there is negligible 
attenuation of the effect of the IL-5-associated SNPs on IL-5 levels when including the lead 
eosinophil-associated SNP as a covariate. The same is observed if the reverse is attempted, 
thus we conclude that the loci are independent.  
 
3.3 Replication of IL5-associated loci 
Ideally we would have liked to replicate both the IL-5 and eosinophil findings but due to lack 
of applicable cohorts it was only possible to attempt replication for the IL-5-assocaited SNPs. 
Characteristics of the replication cohorts are presented in Supplementary Table 1. Replication 
was attempted in 2 independent European cohorts for the IL-5-associated loci, namely 
rs56183820 on chromosome 5 and rs4902762 on chromosome 14. The size of effect in the 
replication meta-analysis (Table 4) was similar to that seen in the discovery analysis, however 
the direction was inconsistent and the associations were solidly non-significant.  
 
3.4 IL-5 and eosinophil-associated SNPs in relation to IMT 
Our aim was to use a Mendelian randomization approach to assess whether the IL-5 or 
eosinophil-associated loci influenced measures of IMT. As we were not able to replicate the 
association of the chr 5 locus with IL-5 levels, conducting a Mendelian randomization 
experiment was unjustified. However, we did assess the effect of these SNPs on IMT 
measures. Considering 6 independent loci (3 previously reported SNPs, 1 eosinophil-
associated locus and 2 IL-5-associated loci), the Bonferroni-corrected significance threshold 
was set at p<0.0083. No associations were observed between the SNPs and baseline measures 
of IMT (Supplementary Table 2). Eosinophil-associated SNPs demonstrated nominally 
significant associations with progression of IMT-CCmax, but only rs2706399 (the G allele of 
which was previously associated with increased CVD risk [6]) met the Bonferonni-corrected 
p for significance (G allele, Beta -0.008, 95%CI (-0.012, -0.004), p = 0.0017, Supplementary 
Table 3). Further adjustment for emerging or established CVD risk markers had negligible 
effect on the associations (Supplementary Table 3). Inclusion of eosinophil count in the model 
rendered the eosinophil-associated SNPs non-significant, but did not have an effect on the 
assocation of rs2706399 (CVD-associated) with IMT-CCmax progression (Supplementary 
Table 3). 
 
3.5 Expression QTL 
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To identify functional effects of the IL-5 or eosinophil-associated loci, SNPs which met the 
threshold for p<1.00E-5 were examined for influence on expression of genes at the locus. In 
the ASAP study, aorta (adventitia and media) and heart tissues were examined. A region 
250kb up and downstream of the lead SNP was defined for each locus, and genes within this 
region were assessed for genotype-specific expression. Bonferroni correction was made for 3 
tissues and 4 loci (one on chromosome 14, 3 on chromosome 5, p for significance <0.0042, 
(Supplementary Figure 2)). The chromosome 14 region included 2 genes, CTAGE5 and 
FBXO33 and rs4902762 was associated with CTAGE5 expression levels in heart tissue 
(p=0.0073), but this did not reach statistical significance. The chromosome 5 eosinophil- and 
IL-5-associated loci overlapped to a large degree, and included many genes (P4HA2 and 
PDLIM4 (eosinophil count locus), SLC22A4, SLC22A5, IRF1, IL5, RAD50, IL13, IL4, KIF3A 
and SEPT8 (both loci), SHROOM1, GDF9, UQCRQ, LEAP2 and AFF4 (IL-5 locus). 
Rs12652920 was associated with RAD50 expression in aortic media (p=0.0093), but this did 
not reach the level of statistical significance. The MuTHER lymphocyte data [32] supports a 
positive effect of the rs4705959 T allele (associated with increased eosinophil count) on 
mRNA expression of RAD50 and SLC22A5, but a negative effect on expression of IL5 (Table 
5). The C allele of rs12652920 (associated with increased IL-5 levels) was also associated 
with increased mRNA expression of RAD50 (Table 5). The rSNPBase was queried to identify 
proxies (r2> 0.8) for the lead SNPs and whether they have been reported to influence 
expression of genes. For the IL-5-associated locus (rs56183420) 63 proxies were identified, of 
which 47 reported eQTL effects on RAD50 but only 24 for IL5. Of note, 35 of these SNPs 
were available in the IMPROVE cohort, all showed associations (p<1.00E-4) with IL-5 levels, 
but not eosinophil count. For the eosinophil-associated loucs (rs72797327) 4 proxies were 
identified, of which 2 each were reported for effects on IL-5 and RAD50 expression, but  all 4 
reported effects on SEPT8 expression. Of these SNPS, all 3 that were available in IMPROVE 
showed strong (p<1.00E-5) effects on eosinophil but not IL-5 levels. Considering the 
chromosome 14 locus, 23 proxies were identified with 5 influencing CTAGE5 expresison and 
7 influencing FBXO33 levels. Only one proxy was available in IMPROVE and was associated 
with IL-5 levels but not eosinophil count.  
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4. Discussion 
 
This study identified genetic regulators of plasma IL-5 levels and eosinophil count, however 
the lack of replication of the genetic associations precludes the ability to formally assess the 
causality of IL-5 levels on IMT. To the best of our knowledge this is the largest study with 
measurement of IL-5 levels and the first to investigate genetic regulation of IL-5 levels.  
 
The genetic loci associated with IL-5 levels and eosinophil count are in close proximity to 
each other and in the vicinity of the IL5 gene on chromosome 5, but act independently. Earlier 
studies identified SNPs in the region of the IL5 and IL5a genes as being associated with 
inflammatory bowel disease (rs2188962 [34]), eosinophil count (rs4143832 [14]) and 
coronary artery disease (rs2706399 [6]). These variants were present on the combined chip 
and thus were also analysed. No association was observed between rs2706399 and either IL-5 
levels or eosinophil count (Supplementary Table 5). In contrast, rs2188962 demonstrated 
nominal associations and rs4143832 demonstrated convincing associations with IL-5 levels 
and eosinophil count (Supplementary Table 5). In agreement with Gudbjartsson et al, the 
minor allele of rs4143832 was associated with eosinophil count [14] as well as IL-5 levels. Of 
note, whilst these SNPs demonstrate some significance in relation to levels of IL-5 or 
eosinophil count, they do not reach the preset level of significance for being forwarded to 
replication analysis. Rs4143832 and rs2706399 are located within the eosinophil-associated 
locus reported here but are independent from the SNPs studied here (by LD, Supplementary 
Table 2). 
 
Whilst SNPs at the loci identifed here do show some associations with IL5 mRNA levels, 
expression of the RAD50 gene demonstrates stronger and more consistent associations across 
the loci. The results from rSNPBase are less clear, and whilst they do support RAD50 as a 
possible candidate, they suggest that SEPT8 (chromosome 5) and FBXO33 (chromosome 14) 
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might also be relevant. Recently, up-regulation of RAD50 and other double-strand repair 
proteins was reported in vascular smooth muscle cells from atherosclerotic plaque [35]. The 
authors suggest that these proteins are associated with plaque stability rather than 
atherosclerosis. Thus it is plausible that the IL5 locus influences plaque stability via RAD50-
associated mechanisms rather than IL-5-associated mechanisms. This speculative mechanism 
fits with the IL5 locus being associated with MI [6] and unstable angina [36], typically 
resulting from plaque rupture, but not with IMT, which is indicative of vessel wall 
remodelling.  
 
Eosinophil count and IL-5 levels are closely inter-connected: IL-5 is essential for eosinophil 
maturation and differentiation [37]. Conversely, eosinophil-specific granules store IL-5 [38], 
indicating that these cells might also contribute to increasing circulating IL-5 levels. In 
IMPROVE, there is a strong correlation between IL-5 concentrations and eosinophil count 
(Spearmans rho=0.560, p<0.001) [11]. Thus it is interesting that these 2 variables are 
regulated by independent loci in the same genetic region. One possibility is that a common 
factor, potentially RAD50, regulates both IL-5 levels and eosinophil count. An alternative 
scenario is that, given the roles of IL-5 and eosinophils in inflammation, upregulation of 
RAD50 might be a DNA-protective stress response mechanism. This would explain the 
puzzling finding that the allele associated with increased eosinophil count shows increased 
RAD50 and the inverse effect on IL5 gene expression, whilst the allele associated with 
increased IL-5 levels also shows increased RAD50 gene expression. It is of note that 2 of the 
top eQTL SNPs for RAD50 [39] are those with the strongest associations with eosinophils 
(rs11739623 and rs4705959) in IMPROVE. Previous reports have demonstrated the use of 
studying specific immune cell types to explore immune or inflammation-related diseases [40, 
41]. Whilst the relationship between the SNPs, RAD50 expression, IL-5 levels and eosinphil 
counts requires clarification, these findings are of potential relevance for eosinophil-
associated disorders.  
 
Whilst this is the largest study with detailed IMT measures, plasma IL-5 concentrations and 
extensive genetic data for all subjects, there are limitations to the study. This study was 
conducted in subjects with at least 3 classical CVD risk factors, thus findings might not 
pertain to other populations. A sex difference in IL-5 levels has been reported [11], thus sex-
stratified analyses would be of interest. However, this approach has not been used here, for 
two reasons: the distribution of outliers (≥1.5 interquartile range above the upper quartile) 
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between men and women might explain the sex difference in levels. Because of this and the 
loss of power when stratifying the analyses, we believe that the chance of detecting false 
positive signals is too high for this analysis to be robust. The lack of Th2 count or 
measurements of Th2 cytokines mean that we cannot conclusively determine the origin of IL-
5 and whether Th2 responses are activated in these subjects. However, it has previously been 
shown that the percentage of Th2 cells has only a very weak (non significant) correlation with 
IL-5 levels released by activated leukocytes [28]. The genotyping chips employed in this 
study are based on a large scale candidate gene/loci experiment, which allows a less stringent 
significance threshold for the discovery analysis, however the whole genome is not 
represented. Thus we cannot comprehensibly describe the genetic architecture of the IL-5-
associated locus on chromosome 14, nor can we exclude the possibility that true IL-5-
influencing genetic variants exist which lie within areas of the genome not examined in this 
study. 
 
 
 
5. Conclusions 
This study identified genetic loci on chromosome 5 associated with IL-5 levels and eosinophil 
count. Whilst these loci are close together in the vicinity of the IL5 gene, they are 
independent. Furthermore, expression analysis suggests RAD50, rather than IL5, as a prime 
candidate gene for these associations. An additional locus associated with IL-5 levels was 
observed on chromosome 14. This report suggests that these loci have negligible influence on 
IMT measures. 
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Figure Legends: 
Figure 1: Manhattan plots of associations between SNPs on the combined chip with A) 
plasma IL-5 levels and B) eosinophil count. Associations were adjusted for age, sex and 
population stratification. The horizontal line at -log10 p value = 5 indicates the threshold for 
replication. 
 
Figure 2: Regional plot of SNPs in the chromosome 5 loci which are associated with A) 
circulating IL-5 concentrations and B) eosinophil count. The purple diamond indicates 
rs12652920 (the lead SNP in the IL-5-associated locus), and thus demonstrates that the lead 
SNP in the eosinophil-associated locus (rs57896917) is independent by linkage 
disequilibrium. 
 
Supplementary Figure 1. Regional plot for a locus on chromosome 14 associated with plasma 
IL-5 concentrations. 
 
Supplementary Figure 2. Linkage disequilibrium (LD) between candidate SNPs and those 
associated with IL5 levels or eosinophil count in the IMPROVE study (at p<1.00E-5). Block 1 
consists of eosinophil-associated SNPs and blocks 2 and 3 are IL5-associated SNPs. The 
candidate SNP rs2188962 (Irritable bowel disease-associated [34]) falls outside of the 2 novel 
loci described in this report, whilst the eosinophil count and CVD-associated SNPs 
(rs4143832 [14] and rs2706399 [6] respectively) are located within the novel eosinophil 
count-associated locus. Colours and values reflect R2 measures of LD.  
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